Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy

Clinical and Experimental Rheumatology

Volumn 25, Issue 4, 2007, Pages 613-616

  Paone, Carmen ^a   Chiarolanza, Ilaria ^a   Cuomo, Giovanna ^a   Ruocco, Luigia ^a   Vettori, Serena ^a   Menegozzo, Massimo ^a   La Montagna, Giovanni ^a   Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Azathioprine; Systemic sclerosis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOMPERIDONE; NIFEDIPINE; OMEPRAZOLE; STEROID;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; MAINTENANCE THERAPY; MALE; PATIENT SAFETY; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYSTEMIC SCLEROSIS; TREATMENT DURATION;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSE THERAPY, DRUG; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 34648822788     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. FURST DE, CLEMENTS PJ, SEIBOLD JR: Treatment of Systemic Sclerosis by Potentially Disease - Modifying Drugs. In: CLEMENTS PJ, FURST DE (Eds.) Systemic Sclerosis. 2nd Edition. Lippincott Williams and Wilkins. Philadelphia. 2004: 351-61.
2. SILVER RM, WARRIK JH, KINSELLA MB, STAUDT LS, BAUMAN MH, STRANGE C: Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993; 20: 838-44.
3. AKESSON A, SCHEJA A, LUNDIN A, WOLLHEIM FA: Improved pulmonary function in systemic sclerosis after treatment with cyclophasphamide. Arthritis Rheum 1994; 37: 729-35.
4. WHITE B, MOORE WC, WIGLEY FM, XIAO HQ, WISE RA: Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
5. PAKAS I, IOANNIDIS JPA, MALAGERI K, SKOPOULI FN, MOUTSOPOULOS HM, VLACHOYIANNOPULOS PG: Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
6. GIACOMELLI R VALENTINI G, SALSANO E et al.: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
7. AIRÒ P, DANIELI E, PARRINELLO G et al.: Intravenous cyclophosphamide therapy for systemic slerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheum 2004; 22: 573-8.
8. APRAS S, ERTENLI I, OZBALKAN Z et al.: Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 2003; 48: 2256-61.
9. TASHKIN DP, ELASHOFF R, CLEMENTS PJ et al.: Cyclophosphamide versus Placebo in Scleroderma Lung Disease. N Engl J Med 2006; 354: 2655-66.
10. VALENTINI G, PAONE C, LA MONTAGNA G et al.: Low-dose intravenous cyclophosphamide in systemic sclerosis: An open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol 2006; 35: 35-8.
11. PLOTZ PH, KLIPPEL JH, DECKER JL et al.: Bladder complication in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979; 91: 221-3.
12. TALAR-WILLIAMS C, HIJAZI YM, WALTHER MM et al.: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-84.
13. KNIGHT A, ASKLING J, GRANATH F, SPAREN P, EKBOM A: Urinary bladder cancer in Wegener's granulomatosis: Risks and relation to cyclophosphamide. Ann Rheum Dis 2004; 63: 1307-11.
14. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis: The Euro-Lupus; Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous yclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
15. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
16. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
17. MARTIN-SUAREZ I, D'CRUZ D, MANSOOR M, FERNANDEZ AP, KHAMASHTA, HUGHES GR: Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-7.
18. CLEMENTS P, LACHENBRUCH P, SIEBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
19. POOLE JL, STEEN VD: The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 27-31.
20. AMERICAN THORACIC SOCIETY STANDARDIZATION OF SPIROMETRY, 1994 update. Am J Respir Crit Care Med 152: 1107-36.
21. OGILVIE CM, FOSTER RE, BLAKEMORE WS, MORTON JW: A standardized breath holding technique for clinical measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957; 36: 1-17.
22. WHITE B, BAUER EA, GOLDSMITH LA et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). 1. Disease-modifying interventions. The American College of Rbeumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. Arthritis Rheum 1995; 38: 351-60.
23. MEDSGER TA, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 1999; 26: 2159-67.
24. VALENTINI G, MEDSGER TA Jr, SILMAN AJ, BOMBARDIERI S: The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003; 21(Suppl. 29): S1-56.
25. MERKEL PA, HERLYN K, MARTIN RW et al.: Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 2410-20.
26. KHANNA D, FURST DE, HAYS RD et al.: Minimally important difference in diffuse systemic sclerosis-results from the D-Penicillamine study. Ann Rheum Dis 2006; 65: 1325-9.
27. MEDSGER TA JR: Classification, Prognosis. In: CLEMENTS PJ, FURST DE (Eds.) Systemic Sclerosis. 2nd Edition. Lippincott Williams and Wilkins. Philadelphia. 2004: 17-28.
28. CZIRJAK L, KISS CG, LOVEI C et al.: Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Trandanubian Hungarian inhabitants. Clin Exp Rheumatol 2005; 23: 801-8.
29. JUN JB, CHO DY, KANG C, BASE SC: Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005; 23: 873-6.
30. ZANDMAN-GODDARD G, TWEEZER-ZAKS N, SHOENFELD Y: New therapeutic strategies for systemic sclerosis - a critical analysis of the literature. Clin Dev Immunol 2005; 12: 165-73.